Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
Detailed price information for Artelo Biosciences Inc (ARTL-Q) from The Globe and Mail including charting and trades.
CUPE Alberta Responds to Continued Alberta Government Interference in Public Sector Pension Plans
The Government of Alberta’s unilateral changes to AIMCo’s board without any consultation with public sector unions representing members in the Local Authorities Pension Plan (LAPP) and the Public ...
Artelo Biosciences announces acceptance of ART26.12 into NIH PSPP program
Artelo Biosciences (ARTL) announced that ART26.12, the Company’s lead clinical FABP inhibitor, has been accepted into the NIH Helping to ...